Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Migden is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Dermatology, 1998 - 2001- Mayo Clinic College of Medicine and Science (Rochester)Internship, Internal Medicine, 1997 - 1998
University of Utah School of MedicineClass of 1997
Certifications & Licensure
TX State Medical License 2003 - 2027
AZ State Medical License 2000 - 2021
OK State Medical License 2020 - 2021
MN State Medical License 1999 - 2018
FL State Medical License 2001 - 2017
WI State Medical License 2003 - 2017
American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2015
- Fellow (FAAD) American Academy of Dermatology
- Fellow (FASDS) American Society for Dermatologic Surgery
Clinical Trials
- Spectral Diagnosis of Cutaneous Malignancy Start of enrollment: 2007 Apr 01
Publications & Presentations
PubMed
- Epidemiology of Eccrine Porocarcinoma in the United States: A Study of 948 Cases.Tejas P Joshi, Sarah E Rashdan, Michael R Migden
International Journal of Dermatology. 2026-08-01 - HSR26-247: Real-World Quality of Life in Patients Treated With Cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma: Results of CemiplimAb Survivorship Epidemiolo...Guilherme Rabinowits, Soo J Park, Nikhil I Khushalani, Timothy Panella, David M Ellison
Journal of the National Comprehensive Cancer Network. 2026-03-31 - HSR26-247: Real-World Quality of Life in Patients Treated With Cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma: Results of CemiplimAb Survivorship Epidemiolo...Guilherme Rabinowits, Soo J Park, Nikhil I Khushalani, Timothy Panella, David M Ellison
Journal of the National Comprehensive Cancer Network. 2026-03-31
Journal Articles
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaJade Homsi, Michael R Migden, Nikhil I Khushalani, The New England Journal of Medicine
Lectures
- Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).2019 ASCO Annual Meeting - 6/1/2019
- 42-month follow-up of sonidegib efficacy and safety in advanced basal cell carcinoma: Final analysis from BOLT.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
Parting Advice on Non-Melanoma Skin Cancer ManagementJuly 22nd, 2019
Clinical Challenges: What’s Next for Cutaneous Squamous Cell Carcinoma?June 15th, 2019
First Treatment Approved for Common Form of Advanced Skin CancerOctober 1st, 2018
Professional Memberships
- Fellow
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
